Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
life science investing Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
West High Yield Resources Ltd. Corporate Update: Initial Reclamation Bond Posted, Permit Conditions Advancing, and Construction Pathway Strengthening for 2026